MAPK1 and cancer: Emerging data underscore that LSAMP losses in the setting of cancer can increase the expression of receptor tyrosine kinases on the surface of the cell, leading to the increased activation of tumorigenic ERK and Akt pathways and the increased activation of β-catenin (Figure 2).